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Background
Juvenile idiophatic arthritis (JIA) is a heterogeneous dis-
ease and it’s associated with an increased use of various
biological agents in recent years.
Aim
Describe changes in treatment with biological agents in
JIA patients.
Methods
This is a retrospective study of 109 JIA patients from a
tertiary centre. Variables included were: age, disease
d u r a t i o n ,s e x ,a n t i n u c l e a rantibodies (ANA), HLA B27,
Rheumatoid Factor (RF), uveitis and data of systemic
AIJ. Current and previous biological agents, reasons for
change and adverse events were also recorded.
Results
The sample included 83 girls and 26 boys aged 10 ± 4.4
(2.4-19.6) with a disease duration of 5 ± 3.4 (0.1- 17)
years. The initial biological agent was etanercept (ETA)
in 87 cases, adalimumab (ADA)i n9 ,a n a k i n r a( A K )i n
12 and infliximab (IFX) in 1. Twenty-eight patients
switched to a second biological agent, 7 to a third and 2
to a fourth. Switching was due to inefficacy since
adverse events were mild or moderate.
Current treatment with ETA was associated with ANA
positives (p=0,032), however ADA did so with uveitis
(p=0,000) and AK y TCZ with s-JIA (p=0,000). Table 1
Conclusion
1. Switching to a second biological agent was necessary
in 26% of patients. Only 6% of patients switched to a
third, and 2% to a fourth.
2. The results indicate that etanercept was chosen in
patients with ANA positives, adalimumab in cases with
uveitis and anakinra and tocilizumab in those with sys-
temic symptoms.
Table 1 Patient characteristics and biological agent treatment
Current treatment Sex M/F ANA (+) HLA B27 (+) RF (+) Uveitis Data of s-JIA Previous treatments
ETA n=58 11/47 19 (33%) 13 (22%) 2 (3%) 11 (19%) ADA n=1
ADA n=16 2/14 6 (38%) 3 (19%) 14 (88%) 1 (7%) ETA n=8
IFX n=1
AK n=9 5/4 1 (11%) 9 (100%) ETA n=2
TCZ n=11 3/8 1 (9%) 6 (55%) ETA n=7
IFX n=2
AK n=6
ADA n=3
IFX n=2 1/1 2 (100%) ETA n=2
Untreated* n=13 4/9 2 (15%) 2 (15%) 1 (8%) 1** (8%) ETA n=12
AK,TCZ n=1
* In 12 cases ETA was withdrawn due to inactive disease. **One child had episodes of macrophage activation syndrome, being with and without biological
agent.
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